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Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system
characterized by demyelination and axonal degeneration. MS patients typically present
with a relapsing-remitting (RR) disease course, manifesting as sporadic attacks of
neurological symptoms including ataxia, fatigue, and sensory impairment. While there
are several effective disease-modifying therapies able to address the inflammatory
relapses associated with RRMS, most patients will inevitably advance to a progressive
disease course marked by a gradual and irreversible accrual of disabilities. Therapeutic
intervention in progressive MS (PMS) suffers from a lack of well-characterized biological
targets and, hence, a dearth of successful drugs. The few medications approved for the
treatment of PMS are typically limited in their efficacy to active forms of the disease, have
little impact on slowing degeneration, and fail to promote repair. In looking to address
these unmet needs, the multifactorial therapeutic benefits of stem cell therapies are
particularly compelling. Ostensibly providing neurotrophic support, immunomodulation
and cell replacement, stem cell transplantation holds substantial promise in combatting
the complex pathology of chronic neuroinflammation. Herein, we explore the current
state of preclinical and clinical evidence supporting the use of stem cells in treating
PMS and we discuss prospective hurdles impeding their translation into revolutionary
regenerative medicines.
Keywords: progressive multiple sclerosis, neural stem cell, regenerative neuroimmunology, mesenchymal stem
cell, stem cell therapy, clinical trial
INTRODUCTION
Multiple sclerosis (MS) is a chronic neuroinflammatory condition that affects over 2 million people
worldwide (Stenager, 2019). The disease typically manifests in a relapsing-remitting (RR) form
marked by sporadic attacks of neurological dysfunction (i.e., clinical relapses) followed by a (full
or partial) functional recovery. While advances in the development of immunomodulatory disease-
modifying therapies (DMTs) have had a substantial impact on the severity and frequency of relapses
(Derfuss et al., 2020), within 30 years of diagnosis, two-thirds of RRMS patients will ultimately
transition into the debilitating secondary progressive (SP) phase of the disease (Scalfari et al., 2014).
During this phase, patients experience a gradual and ongoing accumulation of disability despite
a lack of clinically evident relapses (Confavreux and Vukusic, 2014). In addition, 10–15% of MS
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patients present with a progressive form of the disease from the
outset, a condition known as primary progressive (PP) MS.
Both forms of progressive MS (PMS) represent unmet
clinical needs, as no available therapy is capable of arresting
and repairing central nervous system (CNS) damage once
progression ensues. Therefore, PMS therapeutic options (beyond
conventional DMTs) should be devised to address the core
drivers of this process to reduce chronic CNS compartmentalized
neuroinflammation, enhance remyelination, and promote neural
plasticity/regeneration.
In this sense, an extensive body of preclinical data supports the
capacity of stem cell therapies to modulate the deleterious host
immune responses and to facilitate neuroprotection in the CNS,
which may be key to treat PMS.
UNDERSTANDING THE
PATHOPHYSIOLOGY OF PMS
The current success of DMTs mostly stems from their action on
the adaptive immune system, a key driver of disease pathogenesis
in the RR phase. Here, DMTs work to prevent acute inflammatory
insults by limiting infiltration of activated T cells, B cells, and
macrophages into the CNS where they contribute to the initial
demyelinating insult that eventually leads to axonal loss and
neurological disability (Mallucci et al., 2015). However, with
increasing age and the subsequent transition of patients into the
progressive phase of the disease, conventional DMTs no longer
have a clear rationale of use nor provide obvious clinical benefits
(Cunniffe et al., 2021). In fact, the progressive form of MS differs
from RRMS in that it is a distinct neurodegenerative process
shaped by persistent inflammation behind a closed blood-brain
barrier (BBB) involving mostly activated microglia/macrophages,
and only partially T and B cells.
Understanding the pathological correlates of disease that
contribute to the transition from RRMS to PMS and identifying
dysfunctional mechanisms in PMS that lead to a persistent
inflammatory disease state in the CNS is pivotal to identify
new therapeutic strategies. Key mechanisms are discussed in the
following sections and summarized graphically in Figure 1.
The Role of Lymphocytes
The activation of lymphocytes and their infiltration into the CNS,
which is typical of the RR forms of MS, is significantly decreased
in PMS (Frischer et al., 2009). In early progressive disease,
infiltration of lymphocytes (T and B cells) is compartmentalized
at the leptomeninges and blood vessels of the CNS, beyond
an intact BBB (Hochmeister et al., 2006). The extent of T cell
infiltrate found within the meninges is directly correlated with
the degree of axonal loss in the normal appearing white matter
(NAWM) (Androdias et al., 2010; Lassmann, 2018). This implies
that T cells, through the secretion of inflammatory factors, may
contribute to CNS inflammation and damage. B cells have also
been found to play a significant role in PMS by accumulating
in the meninges and creating de novo structures called ectopic
follicles (Serafini et al., 2004; Magliozzi et al., 2013). Here, B
cells produce antibodies, secrete cytokines, and present antigens
which further contribute to the persistence of inflammation
(Aloisi and Pujol-Borrell, 2006). In fact, PMS patients presenting
with follicle-like structures have a higher rate of disability and
show a faster disease progression, associated with an increased
lesion burden (Howell et al., 2011). This is thought to be at
least partially the result of the extent and severity of meningeal
inflammation in the formation of subpial cortical lesions (Howell
et al., 2011; Choi et al., 2012). However, not all PMS patients
present with inflammatory follicles, which suggests the presence
of factors other than CNS B cells contributing to the persistent
inflammation observed behind the intact BBB (Magliozzi et al.,
2007). A number of studies have identified the presence of
meningeal follicles only in SPMS and absent in PPMS (Magliozzi
et al., 2007; Choi et al., 2012), yet a few others have identified
follicular structures in PPMS cases associated with a rapid
disease progression (Kutzelnigg et al., 2005; Haider et al., 2016;
Cencioni et al., 2021).
The Role of Mononuclear Phagocytes
In PMS, persistent tissue injury is associated with the activation
of mononuclear phagocytes (MPs), consisting of both the
CNS tissue resident microglia and the infiltrating monocytes
that differentiate into macrophages (Lassmann et al., 2012).
Interestingly, activation of MPs is found in many other
neurodegenerative diseases without the associated pathological
changes observed in MS (such as demyelination), suggesting
that a specific mechanism may be required in MS to induce
disease progression.
MPs in demyelinating lesions produce reactive oxygen species
(ROS), reactive nitrogen species (RNS), and secrete pro-
inflammatory cytokines and chemokines, including interleukin
(IL)-1ß, IL-6, tumor necrosis factor (TNF)-α, and interferon
(IFN)-γ, leading to oligodendrocyte and neuronal cell death. MPs
are found in smoldering lesions, which are lesions unique to
PMS patients that slowly expand due to clusters of activated MPs
at the edge of these lesions (Reich et al., 2018). The continued
activation and spreading of MPs in smoldering lesions contributes
to further disease progression by increasing the size of the lesion
and associated axonal damage (Kutzelnigg et al., 2005). Activated
MPs, identified through their expression of CD68, are also found
in the NAWM and normal appearing gray matter of patients with
PMS. The number of activated MPs within the NAWM correlates
with the extent of axonal injury, as measured by axonal swelling
and degeneration, suggesting the neurodegenerative impact of
diffuse MP inflammation (De Groot et al., 2001; Kutzelnigg et al.,
2005; Absinta et al., 2019).
The Role of Oligodendrocytes,
Astrocytes and Neurons
Failure of the damaged CNS to regenerate and remyelinate
is currently under intense study as the primary reason
behind the transition from RRMS to PMS, since the
presence of demyelinated axons in post-mortem neural
tissue is highly prevalent during this stage of the disease
(Franklin and Ffrench-Constant, 2008).
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FIGURE 1 | Pathology of progressive multiple sclerosis. Subpial lesions are typically found in PMS which are characterized by lymphocyte accumulation in the
meninges. Activated T and B cells can secrete inflammatory cytokines causing microglia and astrocyte activation and ensuing demyelination of the cortex.
Smoldering lesions are characterized by the degeneration of demyelinated neurons and surrounding microglial rim. Demyelinated axons have been found to have
mitochondrial (mt) damage caused by ROS/RNS secretion from activated microglia. ROS/RNS can also oxidize myelin debris to generate oxidized
phosphatidylcholines (OxPCs), which are toxic to neurons. Few oligodendrocyte progenitor cells (OPCs) are seen in these lesions, with no remyelination.
Findings from pre-clinical rodent models of MS have
suggested that oligodendrocyte progenitor cells (OPCs) are
functionally capable of remyelinating demyelinated axons
(Franklin and Ffrench-Constant, 2017). However, recent findings
from human studies have determined that the presence of
myelinating oligodendrocytes in shadow plaques match the
biological age of the patient. This suggests that myelinating
oligodendrocytes within the plaque arise from the rearrangement
of pre-existing oligodendrocytes rather than from newly
generated OPCs (Yeung et al., 2019). Further work in humans
using single cell RNA sequencing has revealed a depletion of
OPCs in the NAWM of the PMS brain, implicating mature
oligodendrocytes in early remyelination. However, significant
differences in the transcriptome of mature oligodendrocyte
populations were identified, including a decrease in intermediate
oligodendrocytes and a skewed distribution of mature
oligodendrocytes, suggesting a decreased regenerative potential
(Jäkel et al., 2019). There remains significant debate as to whether
OPCs are capable of remyelination in the human disease, if they
are impeded by external and intrinsic factors, or if remyelination
is primarily initiated by mature oligodendrocytes.
Astrocytes have been implicated in perpetuating CNS damage
through secretion of inflammatory molecules, such as TNF-α and
ROS that lead to both oligodendrocyte and neuronal cell death
(Yi et al., 2019). In fact, the inhibition of astrocyte reactivity
during experimental autoimmune encephalomyelitis (EAE), a
mouse model of MS, ameliorates disease activity, suggesting a
key role in neuroinflammation (Mayo et al., 2014). In chronic
MS lesions, astrocytes maintain a hypertrophic response and
form a glial scar in order to prevent spread of tissue destruction
(Holley et al., 2003). However, the astrocytic scar can inhibit
both remyelination and axonal regeneration, for example via
the secretion of fibroblast growth factor-2 which promotes OPC
proliferation but prevents differentiation (Goddard et al., 1999;
Thümmler et al., 2019). Astrocytes have also been implicated
in the production of hyaluronan, a glycosaminoglycan that
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accumulates in MS lesions, which can interact with CD44, a
receptor found on neural stem cells (NSCs) (Pluchino et al.,
2005), OPCs, astrocytes, and T cells (Sherman et al., 2002).
The activation of CD44 on T cells induces proliferation and a
cytokine response (Baaten et al., 2010), while treatment of OPCs
with hyaluronan prevents their maturation into oligodendrocytes
(Back et al., 2005).
Astrocytes play a key role in perpetuating inflammation
in the MS CNS through the recruitment and activation of
immune cells. The passage of leukocytes through the BBB is
facilitated through increased expression of adhesion molecules
such as vascular adhesion molecule (VCAM)-1 and intercellular
adhesion molecule (ICAM)-1 on astrocytes. The expression of
VCAM-1 on astrocytes is necessary for the entry and retention
of T cells in the CNS parenchyma of EAE animals, as well as
ensuing neurological disease (Gimenez et al., 2004). Further, the
release of pro-inflammatory factors by astrocytes at the BBB
such as IL-1ß, TNF-α, and chemokines C-C motif ligand 3
(CCL3) and C-X-C motif ligand 12 (CXCL12), attracts peripheral
immune cells and increases permeability, thus allowing for
their passage into the CNS (Minagar and Alexander, 2003;
Calderon et al., 2006). Lastly, astrocytes affect the phenotype of
T cells and microglial/macrophage activity in the CNS. Cytokines
secreted by astrocytes promote the polarization of T cells and
microglia/macrophages into pro-inflammatory states (Th1/Th17
and M1-like, respectively) (Saikali et al., 2010; Toft-Hansen et al.,
2011; Zhou et al., 2011).
Neuronal damage is the key driver of brain atrophy, the
prominent pathological feature of PMS (Bermel and Bakshi,
2006). Secondary, immune-mediated damage to neurons by
peripheral lymphocytes is more common in the relapsing stage
of the disease (Dutta and Trapp, 2011). On the other hand,
primary neuronal damage is the key mechanism of damage in
the progressive phase of the disease. Persistent demyelination
of the axon – especially that driven by inflammatory factors
such as ROS and cytokines – also renders the neuron more
vulnerable to damage.
In PMS, neurons show impaired mitochondrial activity
as evidenced by the decreased density of mitochondrial
complexes I and III, resulting in a deficiency in the ability
to generate energy to sustain normal cellular function (Friese
et al., 2014). Mitochondrial DNA (mtDNA) deletions in
genes that code for catalytic complexes’ subunits necessary
for oxidative phosphorylation have been identified in PMS
(Campbell et al., 2011), and analysis of common mtDNA
sequence variations in MS populations identified a specific
haplotype associated with an elevated risk of incurring mtDNA
deletions in PMS (Tranah et al., 2015). The cumulative
effect of mitochondrial abnormalities in neurons leads to the
increased vulnerability of axons to external damaging stimuli
contributing to their eventual degeneration. Interestingly, both
brain atrophy and the number of transected axons correlate
with the degree of inflammation in PMS lesions, suggesting
a link between immune cell activation and neuronal damage
(Frischer et al., 2009).
In this sense, ROS and RNS generated from both subsets of
MPs may be the key drivers affecting mitochondrial functionality
in neurons, thus leading to a highly destructive environment
permissive to continued neuronal death.
The Role of Cell Metabolism and
Oxidative Stress
Metabolic signatures, such as differences in
glycerophospholipids, have emerged as important readouts
of PMS pathology and may aid in the diagnosis and the
understanding of disease progression (Stoessel et al., 2018).
Several metabolites, or breakdown and intermediate products
of cellular metabolism, are known to play important roles
in regulating the inflammatory activity of immune and
nervous system cells (Rothhammer et al., 2016). Succinate, an
intermediate metabolite of the tricarboxylic acid cycle (TCA),
increases and accumulates in the cerebrospinal fluid (CSF) of
animals with EAE. Here, extracellular succinate exacerbates the
pro-inflammatory activity of MPs, which further increased tissue
damage (Peruzzotti-Jametti et al., 2018).
Clinically, analysis of CSF samples from MS patients has
identified increased levels of lactate and altered levels of glucose
in patients with PMS (Lynch et al., 1993; Simone et al., 1996).
Follow-up untargeted mass spectrometry-based metabolomic
studies have also identified alterations in lipid and energy
metabolism in the CSF that are associated with a more severe
disease progression in PMS patients. This may reflect the overall
decrease in lipid content associated with increased demyelination
(Villoslada et al., 2017).
Oxidized phosphatidylcholines (OxPCs) are another possible
driver of neurodegeneration in PMS lesions. OxPCs are generated
when myelin debris encounters free radicals leading to oxidized
myelin. Prominent depositions of OxPCs are found in white
matter lesions in PMS brains and associated with activated
microglia. An in vitro study found OxPCs to be toxic to
cultured neurons and oligodendroctyes (Dong et al., 2021).
The combination of mitochondrial dysfunction, inflammatory
metabolites (such as succinate) and inflammatory ROS/RNS may
further generate OxPCs, thus contributing to the progression
of MS pathology.
The Role of Aging
Age is a prominent factor in the transition to PMS (Sanai et al.,
2016; Scalfari et al., 2016). Several of the hallmarks that are
associated with the aging process, including telomere attrition,
mitochondrial dysfunction, cellular senescence, and stem cell
exhaustion, have been linked to PMS (López-Otín et al., 2013;
Oost et al., 2018). Cellular senescence is a biological process
that can be induced via stress or replicative fatigue, triggering a
variety of intrinsic cell processes including cell cycle arrest and
secretion of a pro-inflammatory senescence associated secretory
phenotype, which can have deleterious effects on the tissue
microenvironment (Coppe et al., 2010).
Senescent progenitor cells are identified in lesions of PMS
patients and associated with increased secretion of the pro-
inflammatory alarmin high mobility group box 1 protein, which
impairs OPC differentiation in vitro (Nicaise et al., 2019). Recent
evidence further demonstrates that, with age, rodent OPCs are
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incapable of differentiating into mature oligodendrocytes which
impairs their potential to regenerate lesioned areas (Neumann
et al., 2019). Changes in OPCs due to aging and inflammation,
such as DNA damage and reduced mitochondrial function, may
account for the loss of remyelination in PMS.
Immunosenescence of macrophages and T and B cells could be
another potential mechanism behind the decreased regenerative
potential of the diseased CNS in PMS. Indeed, senescence of
the immune compartment is understood to play a role in
driving systemic aging in solid organs, including in immune
privileged organs such as the brain (Yousefzadeh et al., 2021).
Here, extracellular cholesterol generated from myelin breakdown
overwhelms the phagocytic capability of aged macrophages and
drastically impairs their ability to clear areas of inhibitory and
damaging cellular debris (Cantuti-Castelvetri et al., 2018). T
cell senescence has been observed in with RRMS and PMS
patients, correlating perturbation of the immune system with
age (Thewissen et al., 2005). Additionally, shorter telomeres,
associated with senescent cells, have been identified in leukocytes
of patients with PMS, with shorter telomere length correlated
with increasing disability (Krysko et al., 2019).
Overall, a significant effect of aging is the increase in
secreted inflammatory factors from senescent cells which can
promote MS progression.
CURRENT AND EMERGING THERAPIES
FOR PMS
DMTs and Their Role in PMS
In RRMS DMTs are largely used to reduce and prevent relapses.
IFN-ß and glatiramer acetate (GA) are immunomodulatory
agents commonly recommended as first-line DMTs for RRMS.
Other first-line DMTs for RRMS include teriflunomide and
dimethyl fumarate (DMF), which are typically recommended
as an option only if patients do not have a highly active or
rapidly evolving severe disease. When these first-line DMTs are
ineffective, the alternative is (1) switching to another first line
DMT or (2) starting a second-line DMT (e.g., natalizumab,
fingolimod, cladribine, alemtuzumab, or rituximab), which has
greater efficacy but also more severe side-effects. This approach is
defined as escalation therapy and is used for most RRMS patients.
In patients presenting with aggressive inflammatory disease
at onset, consensus is that a more beneficial approach is
to employ an induction immune therapy using second-line
DMTs from the beginning of treatment (Roos et al., 2020),
conferring a significantly lower risk of SPMS conversion (versus
first-line escalation therapy) (Brown et al., 2019). Such an
approach is more effective in reducing the risk of reaching
a disability milestone, albeit with a worse safety profile
(Prosperini et al., 2020).
Despite DMT treatment, the majority of RRMS patients will
eventually experience a change in their MS, with fewer or no
relapses over time but increasing disability and a decline in
neurological function, reflecting an SPMS pattern (Inojosa et al.,
2019). The transition from predominantly relapsing forms to
more progressive forms of MS is gradual, and the two phenotypes
inherently overlap for a period. In these transitional forms of
MS, clinicians tend to continue the use of DMTs because of
uncertainty in making a firm SPMS diagnosis, reluctance to stop
treatment, and patients’ fear of disease activity returning upon
withdrawal. However, the overall benefits of this approach are
dubious, as many DMTs approved for RRMS showed negative or
inconsistent results in clinical trials centered on SPMS patients
(Fox et al., 2012). IFN-ß (Leary et al., 2003), GA (Wolinsky et al.,
2007), fingolimod (clinicaltrials.gov identifier NCT00731692),
and natalizumab (NCT01416181) (Kapoor et al., 2018) have all
shown no clear efficacy in PMS patients.
Until recently, IFN-ß was the only DMT approved by
the United Kingdom National Institute for Clinical Excellence
(NICE) for people with SPMS, but only in the case of
patients experiencing continuing relapses (i.e., active SPMS) (La
Mantia et al., 2013). This recommendation came from evidence
suggesting that IFN-ß reduced relapse risk in SPMS patients
but was unable to significantly slow disability progression versus
placebo (Panitch et al., 2004). The antineoplastic mitoxantrone
was also approved as a potential therapy for SPMS by the US
Food and Drug Administration (FDA), despite serious adverse
effects related involving cardiotoxicity and therapy-related acute
leukemia (Martinelli Boneschi et al., 2013).
Ocrelizumab (Ocrevus), a humanized anti-CD20 monoclonal
antibody, was approved for PPMS patients by the FDA in 2017
and by NICE in 2019. The use of anti-CD20 antibodies stems
from the initial observation that a single intravenous course
of the anti-CD20 antibody rituximab reduces the inflammatory
brain lesions in RRMS patients (Hauser et al., 2008). These data
provided evidence of B-cell involvement in the pathophysiology
of MS and prompted the use of anti-CD20 antibodies in
PMS patients. Despite initial setbacks (Hawker et al., 2009),
ocrelizumab was approved for patients with active PPMS
thanks to the results of the ORATORIO study (Montalban
et al., 2017); it is recommended for PPMS patients fulfilling
specific clinical and radiological criteria consistent with early
active disease.
In 2019, siponimod (Mayzent), a modulator of the
sphingosine-1-phosphate (S1P) receptor (−1 and −5) (Gergely
et al., 2012), was approved by the FDA as the first ever oral
treatment for people with active SPMS, with NICE approval
following the next year. Siponimod is a close structural analog
of S1P, a naturally occurring bioactive sphingolipid that plays
a key role in inflammation and repair processes. The S1P
receptor is expressed by several CNS cells, including astrocytes,
oligodendrocytes, neurons, microglia, and dendritic cells
(Groves et al., 2013). By acting as a functional antagonist on
S1P1 receptors on lymphocytes, siponimod prevents egress
from lymph nodes, reducing the recirculation of T cells into the
CNS to limit central inflammation. Moreover, siponimod can
penetrate into the CNS and distribute into the white matter.
Siponimod approval came after the results of the phase 3
EXPAND study (Kappos et al., 2018); it is recommended for
treating active SPMS in adults.
Despite advances in PMS treatment, major hurdles still exist
as these DMTs are limited to use in patients with an Expanded
Disability Status Scale (EDSS) ≤ 6.5 due to lack of evidence in
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those with more severe disability. Moreover, no treatments are
available for progressive patients who do not experience an active
form of disease, making the identification of new therapies a key
priority of MS research.
Emerging Therapies for PMS
In recent decades several experimental or repurposed drugs have
been tested in PMS but failed to advance past early phases of
clinical testing due to a lack of efficacy (Ontaneda et al., 2017).
These negative outcomes were disheartening, but also fostered
the formation of several consortia aimed at identifying novel
candidates for PMS treatment.
A recent combined systematic approach has reviewed existing
evidence of human safety, BBB penetrance, demonstrable
efficacy, and mechanistic targeting of licensed drugs for
repurposing in PMS (Cunniffe et al., 2021). By focusing
on processes and mechanisms of action that are specifically
relevant to the pathogenesis of progression, four treatments were
recommended for immediate testing in PMS: (R)-α-lipoic acid,
metformin, the combination treatment of both (R)-α-lipoic acid
and metformin, and niacin.
(R)-α-lipoic acid is a cofactor for at least five enzyme
systems including pyruvate and α-ketoglutarate dehydrogenases,
key enzymes of the TCA cycle. Results of a phase 2/3 trial
in MS showed that treatment with lipoic acid induced a
68% reduction in annualized Percent Change Brain Volume
while maintaining favorable safety, tolerability, and compliance
over 2 years (Spain et al., 2017). Metformin, a synthetic
derivative of guanidine commonly used as an oral antidiabetic,
can reverse aging-associated remyelination failure, suggesting a
possible application in PMS (Neumann et al., 2019). Niacin,
a nicotinamide adenine dinucleotide precursor used for the
treatment of hypercholesterolemia, has been shown to be
protective against activated microglial-induced neurotoxicity
and to promote oligodendrocyte proliferation in vitro (Kaneko
et al., 2006). These mechanisms of action could be exploited in
promoting regeneration and repair in PMS.
Besides these repurposed drugs, other therapies currently
being tested in PMS include simvastatin, biotin, cladribrine,
masitinib, ibudilast, and epigallocatechin-3-gallate (Faissner
et al., 2019). Simvastatin has been studied in MS for
its neuroprotective effects, which in part depend on the
improvement of cerebrovascular hemodynamic (Neuhaus et al.,
2004). A randomized, double-blind, placebo-controlled phase 2
clinical trial (MS-STAT) has shown that high dose simvastatin
significantly reduces brain atrophy and radiological lesions in
SPMS patients (Chataway et al., 2014). A larger phase 3 follow-up
(MS-STAT2; NCT03387670) is now ongoing and will hopefully
confirm these benefits. Biotin (vitamin B7) has been shown to (i)
activate myelin formation in oligodendrocytes through its role
as a cofactor for acetyl-CoA carboxylase, and to (ii) increase
ATP production in axonal mitochondria, being a co-enzyme
for three carboxylases (including the pyruvate carboxylase) of
the TCA cycle (Sedel et al., 2015). The preliminary results of a
phase 3 trial (NCT02220933) have shown that high dose daily
administration has an impact on SPMS in reducing disease
progression (Tourbah et al., 2016). A bigger cohort in a phase 3
clinical trial is currently being recruited. Cladribrine is approved
for use in RRMS patients but a previous study found no
significant treatment effects in terms of changes in EDSS scores
in PMS (Rice et al., 2000). Nevertheless, cladribine produced
significant sustained reductions in radiological lesion loads.
These positive (but limited) outcomes sparked a new phase 3 trial,
ChariotMS, looking to assess the beneficial role on cladribine on
upper limb function in advanced PMS patients (EDSS between
6.5 and 8.5) (NCT04695080).
To summarize, therapies for PMS patients are beginning
to emerge and hopefully we will experience a new era of
therapeutics acting on the core drivers of disease progression.
Most likely, successful therapeutic agents will have to interact
with multiple processes, modifying chronic inflammation while
enhancing the intrinsic repair of the damaged CNS. While more
rigorous clinical trial design with appropriate endpoints and
longer follow-up times may aid in the successful identification
of safe and efficacious PMS DMTs (Huntemann et al., 2021),
the innate multifunctionality of stem cell therapies offer a
promising alternative route toward addressing the unmet needs
of neuroprotection and neuroregeneration.
THE BASIS OF STEM CELL THERAPIES
FOR THE TREATMENT OF PMS
Despite considerable success in treating RRMS, and a growing
armamentarium of DMTs for combating active forms of PMS,
there are substantial unmet needs for interventions capable of
halting and reversing the chronic degeneration associated with
PMS. In this light, there has been considerable interest in the
presumed regenerative capabilities of stem cell therapies.
Stem cell therapy is a broad concept comprising the
transplantation of different stem cell types sourced from various
tissues into prospective patients for therapeutic effect. The choice
of one cell type over another is based on multiple factors,
but optimal outcomes will necessitate marrying appropriate
mechanisms of action to the pathobiology being addressed.
Hematopoietic Stem Cell Sources
A first important delineation in terms of therapeutic functionality
exists between hematopoietic and non-hematopoietic therapies.
Hematopoietic stem cell (HSC) transplantation was the
earliest cell therapy to emerge for the treatment of MS
and it is currently the only clinically validated approach,
having been imported from the field of hematology where
it is routinely used in treating malignancies (Muraro et al.,
2017a). HSC transplantation works by resetting the immune
system by means of conventional immunoablation followed
by reconstitution of the immune system by the stem cell
graft. This results in the development of a novel immune
system deprived of pathogenic auto-immune cells. Notably,
whether the transplanted HSCs only provide means to overcome
the cytopenia and toxicity caused by the immunosuppressive
conditioning regimen, or whether there is a distinct transplant-
associated anti-inflammatory effect, remains a matter of debate
(Miller et al., 2021). Nonetheless, HSCs have little regenerative
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impact on the CNS as HSCs lack the ability to differentiate
into neurons, astrocytes or oligodendrocytes (Gavriilaki et al.,
2019). Thus, HSC transplantation is primarily efficacious for the
treatment of clinical forms of MS with high inflammatory activity
(i.e., RRMS or active PMS with clinical and/or radiological
evidence of inflammation), but has limited efficiency in the case
of inactive PMS, failing to address the degenerative component of
the disease (Muraro et al., 2017a; Gavriilaki et al., 2019).
Consequently, non-hematopoietic stem cell (nHSC)
transplantation has been embraced as a potential means to
regenerate the damaged CNS in an attempt to offer a therapeutic
solution for PMS.
Non-hematopoietic Stem Cell Sources
While early studies of therapeutic nHSC transplantation typically
sourced cells from embryonic or fetal tissue, the safety, practical,
and ethical issues surrounding their prospective clinical use
have caused current research efforts to shift toward the study
of nHSCs derived from adult tissue (Hentze et al., 2009;
Volarevic et al., 2018).
The most common nHSC types employed in preclinical and
clinical studies of CNS disorders include: (1) mesenchymal
stromal cells (MSCs), a heterogeneous class of multipotent cells
derived from various tissues (Sharma et al., 2014; Hsuan et al.,
2016; Martin et al., 2019); (2) bona fide neural stem cells (NSCs)
derived from neurogenic brain niches (Boese et al., 2018); (3)
pluripotent stem cell-derived NSCs, produced ex vivo through
neural lineage differentiation of isolated embryonic stem cells
(ESCs) (Cao et al., 2011; Tang et al., 2017; Oh et al., 2018; Zhao
and Moore, 2018) or from differentiation of induced pluripotent
stem cells (iPSCs), themselves generated by reprogramming of
somatic cells such as fibroblasts acquired through a minimally
invasive procedure (Takahashi and Yamanaka, 2006; Yu et al.,
2007; Tang et al., 2017); and, most recently, (4) induced NSCs
(iNSCs) obtained by direct reprogramming of a patient’s somatic
cells, bypassing a pluripotent state (Kim et al., 2011; Han et al.,
2012; Lujan et al., 2012; Thier et al., 2012; Daekee et al., 2019).
Mesenchymal stromal cells are a convenient source of nHSCs,
being derived from various autologous or allogeneic tissues
including bone marrow (BM-MSCs), adipose tissue (AD-MSCs),
and the umbilical cord (UC-MSCs). While MSCs have also been
reported to be able to differentiate toward non-mesodermal cells
including neurons, astrocytes, and oligodendrocytes both in vitro
and in vivo, their propensity for neural differentiation in vivo
is limited (Wei et al., 2013; Squillaro et al., 2016). MSCs from
different donors, various sources from the same donor, and even
fractions of the same cell population are highly heterogenous,
making it difficult to accurately establish their therapeutic efficacy
(Bortolotti et al., 2015). Additionally, MSCs have been reported to
exert immunosuppressive properties, raising concerns regarding
patients potentially being at a greater risk of developing cancer
due to the impaired surveillance activity of the immune system
(Hasan et al., 2017).
Somatic NSCs possess several advantages for CNS applications
over other stem cell sources, including their inherent
commitment to the neural lineage, patient-specificity, and a
low tumorigenic risk thanks to their lack of pluripotency and
limited proliferation rate. However, the latter property comes
at the expense of their low expandability in vitro, limiting
the practicality of using somatic NSCs in large quantities.
Additionally, extraction of NSCs from the neurogenic regions of
the brain is difficult, invasive and carries significant risks (Nam
et al., 2015). Indeed, human adult neurogenesis and the existence
of NSC niches within the adult human brain has been a source of
controversy in the scientific community (Lucassen et al., 2020).
Instead, NSCs are almost exclusively sourced from fetal tissue,
limiting their accessibility and raising ethical concerns.
These caveats led to the search for and identification of
alternative sources of NSCs such as those obtained from ESCs
or iPSCs, as well as iNSCs. These derived NSCs can recapitulate
the properties, potency, and therapeutic potential of bona fide
NSCs, making them ideal candidates to pursue regeneration
of the CNS. Additionally, ESCs, iPSCs and iNSCs are readily
expandable in vitro, and, in the case of iPSCs/iNSCs, autologous
origins can minimize issues relating to immunogenicity, although
not necessarily negating them completely (Wood et al., 2016).
iNSCs offer a number of potential therapeutic advantages over
pluripotent sources in that they are readily sourced, ostensibly
easier, faster, and more cost-efficient to generate than iPSCs,
and bypass a problematic pluripotency stage associated with
tumorigenic risks (Erharter et al., 2019). In several cases,
these multipotent sources have been further differentiated to
specific neural lineages for study in a preclinical transplantation
studies, with iPSC-derived oligodendrocyte progenitor cells
(iPSC-OPCs) being a key example in the context of MS
(Chanoumidou et al., 2020).
Nonetheless, it remains unclear to what extent autologous
patient-derived NSCs may retain disease-specific epigenetic
marks could hamper their therapeutic potential or have
deleterious effects on other CNS cells (Nicaise et al., 2019).
Mechanisms of Action for
Non-hematopoietic Stem Cells
Non-hematopoietic stem cells exert their therapeutic function
in a multifaceted fashion, targeting a broad range of deleterious
disease processes, often in a tissue-specific manner, making them
ideal candidates for treating diseases such as PMS with multiple
overlapping pathological mechanisms.
Originally, nHSC stem cell therapy was explored as a
means to revert CNS damage by replacement of damaged
cells by virtue of the self-renewal and potency properties
of the graft. This view was supported by observations of
successful engraftment and differentiation of stem cells into
the CNS following transplantation in preclinical and clinical
studies of CNS disorders. Indeed, multiple studies assessing
stem cell engraftment and differentiation efficiency in several
CNS conditions such as amyotrophic lateral sclerosis, spinal
cord injury, and stroke have reported the successful synaptic
integration of the graft and subsequent regeneration (Zhang
et al., 2019). As touched upon below, transplanted nHSCs
can also integrate in vivo without differentiation, instead
exerting some of their therapeutic effects through mechanisms
implying cell-to-cell interactions with the host. However, it
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is becoming increasingly clear that the therapeutic properties
of nHSC transplantation extend well beyond differentiation,
cell replacement and integration, factors shown to play only a
secondary role in preclinical studies (Pluchino et al., 2005, 2009;
Scolding et al., 2017). The currently accepted scientific view is
that nHSC transplantation primarily exerts its beneficial effects
by regulating the local environment through paracrine effects
including trophic support, immunomodulation and metabolic
signaling (Figure 2).
The neuroprotective and neurotrophic actions of nHSCs
are directly exerted through the secretion of various factors
(Willis et al., 2020). For example, one of the most clinically
advanced NSC products, the CTX fetal NSC line, has been
reported to secrete a complex cocktail of cytokines and
growth factors that promote neurogenesis, axonal sprouting,
and angiogenesis (Sinden et al., 2017). Likewise, it has been
shown that MSCs secrete factors that induce axonal outgrowth
and increase the survival of cells in vitro (Cho et al.,
2009; Kim et al., 2010). Interestingly, MSCs have exhibited
neuroprotective effects at a distance, without the need of their
direct transplantation into the CNS, as a result of their capacity
to secrete paracrine neurotrophic factors via extracellular vesicles
(EVs) (Li et al., 2019; Mansoor et al., 2019). As membranous
vectors of intercellular communication secreted by cells into the
extracellular space, EVs are capable of influencing physiological
and pathophysiological functions by trafficking bioactive cargoes
such as proteins, lipids, and nucleic acids to recipient cells (van
Niel et al., 2018; Xiao et al., 2021). EVs originating from various
cell types are understood to influence the pathogenesis of MS
and EAE (Dolcetti et al., 2020), highlighting their utility as
biomarkers of disease. Conversely, exogenous stem cell-derived
EVs act as delivery vehicles for prospective therapeutic factors
(Wiklander et al., 2019), even demonstrating the ability to cross
the BBB (Jan et al., 2017; Banks et al., 2020). On this basis, EV-
based therapies are now being explored as a promising acellular
alternative to stem cell transplantation, taking advantage of the
stem cell secretome while minimizing disadvantages such as
immunogenicity (Drago et al., 2013; Riazifar et al., 2017; Vogel
et al., 2018; Branscome et al., 2020).
Mesenchymal stromal cells exhibit immunomodulatory
functions via both direct and paracrine interaction with immune
cells. Specifically, MSCs suppress T cell proliferation, inhibit the
production of pro-inflammatory cytokines, and regulate the ratio
of Th2/Th1 activated cells (Glennie et al., 2005; Puissant et al.,
2005; Yanez et al., 2006). MSCs can also arrest B cell cycling and
inhibit their division and antibody production (Corcione et al.,
2006). Moreover, MSCs affect natural killer cells and dendritic
cells by inhibiting their activation and maturation (Ramasamy
et al., 2007; Burchell et al., 2010), and exert immunosuppressive
activity by modulation of regulatory T cell function (Selmani
et al., 2008). Several MSCs-derived soluble factors including
transforming growth factor (TGF)-β1, prostaglandin E2 (PGE2),
hepatocyte growth factor (HGF), indoleamine-pyrrole 2,3-
dioxygenase, NO, and IL-10 have been proposed to mediate
the immunosuppressive effects of MSCs (Gao et al., 2016).
Importantly, previous studies showed that secretory factors
vary greatly in relation to both the origin of MSCs and their
environmental conditions (Mansoor et al., 2019).
Immunomodulatory functions of NSC transplantation have
been primarily described to occur through juxtracrine and
paracrine T cell signaling (Pluchino and Cossetti, 2013), as a
result of their release of factors such as the cytokines IL-10 (Yang
et al., 2009), leukemia inhibitory factor (LIF) (Cao et al., 2011),
and TGF-β2 (De Feo et al., 2017), as well as NO and PGE2
(Wang et al., 2009). Consequently, NSC transplantation inhibits
the peripheral and perivascular activation of proinflammatory
T cells and increases the numbers of anti-inflammatory T
regulatory cells (Tregs) in animal models of MS (Pluchino
et al., 2005; Einstein et al., 2007). In addition to their paracrine
functions, transplanted NSCs exert important anti-inflammatory
effects on the adaptive immune system through cell-to-
cell interactions, leading to reduced proliferation, decreased
activation, and increased apoptosis of proinflammatory T
lymphocytes (Pluchino et al., 2005; Fainstein et al., 2008).
Transplanted NSCs have also demonstrated immunomodulatory
properties through their direct interaction with local cells of the
innate immune system, including macrophages (Cossetti et al.,
2012). These observations are of particular importance for the
treatment of PMS, when macrophages play a pivotal role in
pathogenesis. Specifically, analysis of cell-to-cell interactions at
the perivascular niches revealed the presence of tight contacts
between NSCs and macrophages, established via connexin 43
(Cusimano et al., 2012).
Metabolic signaling has been described as a distinct
mechanism by which stem cells mediate part of their
immunomodulatory function. In local inflammatory
microenvironments NSCs have been shown to engage in a
homeostatic cell competition with MPs by changing their
own metabolism and depleting the extracellular milieu of
inflammatory immunometabolites such as succinate (Peruzzotti-
Jametti et al., 2018). Additionally, cytokine-primed NSCs
increase the secretion of extracellular arginase-1, inhibiting the
proliferation of lymph node cells (Drago et al., 2016), and EVs
derived from NSCs exposed to a pro-inflammatory stimulus
were found to shuttle receptor-bound IFN-γ to recipient cells
wherein it activates Stat1 signaling (Cossetti et al., 2014). NSCs-
derived also harbor functional metabolic enzymes and thus act
as independent metabolic units (Iraci et al., 2017). Conversely,
addressing the chronic activation of mononuclear phagocytes by
means of modulating their mitochondrial metabolism is expected
to be a key target of future molecular and cellular therapies for
PMS (Peruzzotti-Jametti and Pluchino, 2018).
A new phenomenon of mitochondrial transfer has been
found to take place between MSCs and immune cells,
modulating the function of the latter. Macrophages reportedly
enhance their phagocytic capacity and bioenergetics profiles,
and shift to an anti-inflammatory phenotype, following EV-
mediated transfer of mitochondria from MSCs (Han et al.,
2020). A similar phenomenon has been reported in NSCs,
which release EV-trafficked mitochondria that are taken up
by lipopolysaccharide-activated MPs and integrated into the
host mitochondrial network, metabolically reprogramming
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FIGURE 2 | Mechanisms of action for non-hematopoietic stem cells. Following transplantation, non-hematopoietic stem cells can exert their therapeutic effects by:
(1) replacing damaged CNS cells; (2) offering neurotrophic support to CNS cells via paracrine and juxtracrine signaling; (3) affecting immunomodulatory functions on
both the innate and adaptative immune systems via paracrine and juxtracrine signaling, or via direct cell-to-cell contacts; and (4) engaging in metabolic signaling with
cells within their niche. Representative examples of key players in each mechanism are illustrated. BDNF, brain-derived neurotrophic factor; CNTF, ciliary
neurotrophic factor; GDNF, glial cell–derived neurotrophic factor; NGF, nerve growth factor; NT-3, neurotrophin-3; TSP1-2, thrombospondins 1 and 2; VEGF, vascular
endothelial growth factor.
the MPs and reducing their pro-inflammatory activation
(Peruzzotti-Jametti et al., 2021).
Despite findings suggesting nHSCs as promising therapeutic
tools for diseases such as PMS in which tissue repair is
needed and/or inflammation is extensive, clinical translation
of nHSC transplantation has met some barriers. These include
limited engraftment duration, little in vivo differentiation, and
restricted accessibility into damaged sites (Yousefi et al., 2019).
Additionally, the complex functionality of stem cells makes it
difficult to clearly correlate their distinct therapeutic mechanisms
of action and resultant outcomes in clinical studies. In an attempt
to increase the translational success of stem cell-based therapies,
the use of cell-free stem cell products (i.e., stem cell-derived
secretomes or extracellular vesicles) is currently being proposed
as an alternative therapeutic strategy (Bai et al., 2012). The use
of stem cell derivatives may circumvent many of hurdles of
cell therapy including tumorigenicity, immune rejection, high
costs, and time-consuming manufacturing. Moreover, there is
increasing interest in engineering of stem cell lines to increase
their production of paracrine regulators. For instance, NSC lines
have been engineered to overexpress specific neurotrophic factors
(Marsh and Blurton-Jones, 2017) while the neuroregulatory
platform of the MSC-derived secretome has been modified by
dynamic culturing of MSCs in computer-controlled bioreactors
(Yousefi et al., 2019).
Practical Considerations of Stem Cell
Transplantation Therapy
The specific parameters regarding the optimal administration
route, dose and timing for successful stem cell interventions
are dictated by the cell type being administered and their
mechanisms of action. Multiple prospective administration
routes are available for CNS applications, each of which comes
with its own pros and cons. The least invasive route is the
intravenous (IV) injection (Wang et al., 2017). Of note, this
systemic route is characterized by poor engraftment efficiency
due to the entrapment of stem cells in organs including the lungs,
spleen, bone marrow, and kidneys, preventing most cells from
reaching the CNS parenchyma (Fischer et al., 2009; DePaul et al.,
2015). Nevertheless, while IV injection of stem cells may not be
the optimal method for direct cell replacement, it has instead
the potential to be highly effective for cells which primarily
exert their therapeutic effect through long distance paracrine
modulation, such as MSCs. Alternatively, intraarterial injection
of stem cells has been proposed to prevent the collection of
cells in systemic organs and increase the incidence of cells
reaching their CNS targets (Walczak et al., 2008; Argibay et al.,
2017; Na Kim et al., 2017). However, caution should be taken
when using this administration route as it runs the risk of
causing microembolisms if the volume and concentration of
injected cells are not carefully controlled (Argibay et al., 2017;
Na Kim et al., 2017).
More invasive administration routes ranging from
intrathecal (IT), intracerebroventricular (ICV), and even
direct intraparenchymal (IP) injection have been proposed as
efficient means of facilitating intracranial migration to sites of
damage (Muir et al., 2011; Hurst et al., 2013; Donega et al., 2014).
IP injection may not be a feasible option for PMS stem-cell
transplantation because of the multicentric and/or diffuse
nature of PMS lesions. Thus, administration of NSCs into the
CSF by IT or ICV injection establishes a useful compromise
between the invasiveness of the procedure and circumvention
of biological barriers and may represent the best options with
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regards to the treatment of PMS (Scolding et al., 2017). Lastly,
the transplantation of stem cells through the nasal cavity has
been described as a novel non-invasive approach that ostensibly
results in an effective migration into the CNS. However, the
safety, migratory mechanisms, and overall efficacy of this
procedure are still being studied, and additional reports are
needed to properly assess the safety and reproducibly of this
administration route (Li et al., 2015).
The optimal window for stem-cell administration is another
key consideration to ensure the best clinical outcome. Specifically,
while the early administration of nHSCs may prove beneficial
as the graft counteracts neuroinflammation and provides
neurotrophic support, the pro-inflammatory CNS environment
which characterizes early RRMS and active forms of PMS can
adversely affect cell engraftment, differentiation, and survival
(Smith et al., 2020).
It is thus essential that the suitability of the recipient with
respect to the clinical form of MS, the stage of progression, and
the nature of the therapy being delivered are thoroughly assessed
before stem cells are administered.
PRECLINICAL EVIDENCE FOR STEM
CELL THERAPIES IN TREATING PMS
While there is no perfect animal analog of human MS, various
aspects of the disease (acute and chronic inflammation and
demyelination) can be recapitulated across a variety of in vivo
models (Procaccini et al., 2015; Burrows et al., 2019).
Preclinical evidence for the efficacy of stem cell therapy in
PMS has relied heavily on EAE mouse models to recapitulate
the immunologically driven tissue damage observed in PMS.
EAE is typically induced through administration of myelin-
derived antigens (proteolipid protein or myelin oligodendrocyte
glycoprotein). Other methods commonly used to invoke MS-like
pathology include cuprizone- or lysophosphatidylcholine-
induced demyelination, JHM-strain murine hepatitis virus
(JHMV)-caused encephalomyelitis and demyelination in
susceptible rodents, and the shiverer model of congenital
hypomyelination. Promising preclinical evidence of the
safety and efficacy evidence of stem cell transplantation has
been acquired with both HSC and nHSC sources, with a
common theme of transplants resulting in immunomodulation,
neuroprotection, and neurotrophic support in the chronically
inflamed CNS. Below we briefly summarize key findings in
this area, with a particular focus on nHSC experiments (as
summarized in Table 1).
Preclinical Evidence for HSCs
Immunoablation and subsequent reconstitution by means of
autologous HSC transplantation (HSCT) is now seen as a viable
clinical treatment option for early active MS (see section “Clinical
Studies of Stem Cell Therapies in Progressive Multiple Sclerosis”),
with a strong body of supporting preclinical data from EAE
studies extending back several decades (van Bekkum, 2004; Van
Wijmeersch et al., 2008).
In key supporting in vivo rodent experiments, the effectiveness
of post-conditioning syngeneic HSCT (in the form of a bone
marrow transplant) in combatting EAE was found to be highly
dependent upon the timing of the intervention, with early
treatment having substantial preventative outcomes (Karussis
et al., 1992; Karussis et al., 1993) but little effect during the chronic
stages of EAE (Karussis et al., 1993; van Gelder et al., 1993; Burt
et al., 1998; Herrmann et al., 2005). Bone marrow transplant
during the peak of disease greatly reduced spontaneous relapse
rates (van Gelder et al., 1993), while a study of non-myeloablative
conditioning in mice suggests the long-term EAE remission is
dependent on a transplant-associated induction of regulatory T
cells (Meng et al., 2011). Notably, pseudo-autologous transplants,
obtained from syngeneic bone marrow donor mice in the same
stage of EAE as the recipient, were found to be associated
with higher levels of induced relapses than typical syngeneic
treatments, despite similar efficacy with regards to disease
prevention (van Gelder and van Bekkum, 1996).
Allogeneic transplants have typically been found more
effective than syngeneic or pseudo-autologous sources in
preventing relapses in EAE rodents (van Gelder and van Bekkum,
1995, 1996). There may be implications here with regards
to the optimal choice of allogeneic versus autologous HSC
sources for therapeutic use, however, clinical HSCT routinely
employs autologous sources, backed by assuring efficacy and
safety evidence (Alexander et al., 2021; Miller et al., 2021).
Preclinical Evidence for MSCs
Mesenchymal stromal cells have seen extensive study across
multiple disease models, including CNS disorders, as they are
an easily accessible source of autologous or allogeneic somatic
stem cells with the capacity to differentiate into multiple
lineages including mesodermal, ectodermic, and endodermic
cells (Gugliandolo et al., 2020). However, the limited ability of
MSCs to differentiate in vivo (Nombela-Arrieta et al., 2011)
means that the therapeutic effects of MSCs stem largely from
their paracrine effects, secreting cytokines, growth factors, small
RNAs, and EVs (Gugliandolo et al., 2020). The IV injection
of BM-MSCs in mouse models of EAE at the onset (10 days
post-immunization [dpi]) and peak (15 dpi) of disease, but not
during the chronic phase (24 dpi), improves functional outcomes,
decreases inflammatory cell infiltration, induces T cell anergy,
and suppresses pathogenic B cells (Zappia et al., 2005; Gerdoni
et al., 2007). Further evidence for the immunomodulatory role
of BM-MSCs arises from a study where MSCs were transplanted
intraperitoneally at the peak (14 dpi) and again at the chronic
(20 dpi) stages of EAE in mice (Xin et al., 2020). Amelioration of
clinical scores was observed, correlating with reduced CD4+ and
CD8+ T cell activation and proliferation, increased numbers of
Tregs in the spleen, and a shift in the polarization of macrophages
from M1 to M2, ultimately reducing the splenic production
of pro-inflammatory cytokines, IFN-γ and IL-17. Despite these
positive outcomes, transplanted cells were rarely observed in
the CNS parenchyma, in line with notion that the therapeutic
effects of MSCs transplants arise primarily through paracrine
mechanisms taking place peripherally.
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• Improved EAE outcomes when transplanted before the
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• Grafted cells migrated and survived in the spinal cord
and lymphoid organs
• Decreased inflammatory infiltrates
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• Survival and migration of grafted cells into
demyelinating areas
• Increased oligodendrocyte lineage cells surrounding
lesions
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3 and 28 dpi
MOG-induced
chronic EAE in WT
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• Improved EAE outcomes when transplanted before
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• Reduced demyelination and axonal loss
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chronic EAE in WT
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• Reduced inflammatory cell infiltration and demyelination
• Increase in anti-inflammatory Th2 cells and
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• Reduced autoantigen-specific T-cell function
Xin et al., 2020 BM-MSCs from
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• Shifted the polarization of macrophages from M1 to M2
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• Improved motor function outcomes with high-dose EVs
or cells
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IV, 150 µg EVs 18 dpi MOG-induced
chronic-EAE in WT
female mice
• Improved EAE outcomes
• Reduced demyelination
• Decreased neuroinflammation
• Upregulated Treg numbers
(Continued)
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• Localization of grated NSCs around blood vessels
• VLA-4 expression by NSCs
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• Improved EAE outcomes
• Survival and integration of grafted cells
• Accumulation within perivascular infiltrates
• Reduction of extracellular succinate
• Reprogramming of immune cells toward
anti-inflammatory phenotype
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• When administered 0 dpi, disease onset was delayed,
symptoms were reduced, inflammation and demyelination
were decreased
• When administered 10 dpi, ameliorated EAE
symptoms, inhibited proliferation and cytokine production










• Improved functional outcomes
• Reduced neuroinflammation
• Reduced accumulation of CD5+ T cells
• Increase in regulatory T cell populations
• Decreased demyelination and enhanced remyelination
(Continued)
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• Improved EAE outcomes through neuroprotection, not
cell replacement
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• Survival and migration of grafted cells to CNS lesions in
EAE marmosets; differentiation into mature and
myelin-forming oligodendrocytes in EAE marmosets
• Improved EAE outcomes in mice through reduced
inflammatory cell infiltration and demyelination in EAE mice,
but no cell engraftment
• Grafted cell survival in cuprizone mice and partial
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• Reduction of extracellular succinate
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• Astroglial and oligodendroglial differentiation; many
undifferentiated
• Demyelination unaffected but increased endogenous
oligodendrocytes and proliferating OPCs
• Reduced astrogliosis
• Amelioration of motor deficits
BMP, bone morphogenic protein; CNS, central nervous system; dpi, days post-immunization; EAE, experimental autoimmune encephalomyelitis; ESC, embryonic stem
cell; ICV, intracerebroventricular; IL, interleukin; iNSC, induced neural stem cell; IP, intraperitoneal; iPSC, induced pluripotent stem cell; IV, intravenous; JHMV, JHM-strain
murine hepatitis virus; LIF, leukemia inhibitory factor; MEF, mouse embryonic fibroblast; MOG, myelin oligodendrocyte glycoprotein; MSC, mesenchymal stromal cell;
NSC, neural stem cell; OPC, oligodendrocyte progenitor cell; PLP, proteolipid protein; SUCNR1, succinate receptor 1; SVZ, subventricular zone; TMEV, Theiler’s murine
encephalomyelitis virus; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor; WT, wild-type.
Nonetheless, cases of neural differentiation and integration
have been reported. IV injected AD-MSCs successfully integrated
into the spinal cord of mice with EAE at 3 months; most
cells had differentiated into OPCs, but a limited differentiation
into astrocytes or mature oligodendrocytes was also observed
(Constantin et al., 2009). When administered before EAE onset (3
and 8 dpi) AD-MSCs improved functional outcomes and reduced
inflammation. When administered in the chronic phase (23 and
28 dpi) functional deficits were again significantly ameliorated,
endogenous OPCs were increased around the demyelinating
lesions, and the number of anti-inflammatory Th2 cells was
increased (Constantin et al., 2009). In a similar study, AD-
MSCs sourced from either mice or humans were transplanted
intraperitoneally at onset or during the acute phase of EAE and, in
both cases, clinical scores were improved (Anderson et al., 2017).
Further in vitro and in vivo investigation revealed that in mice
with EAE, the transplantation of syngeneic AD-MSCs improved
symptoms by reducing both autoantigen-specific T cell function
and the activation of dendritic cells in draining lymph nodes.
Xenografts of human MSCs in mouse models of EAE have had
similar success when compared to their mouse counterparts. The
IV transplantation of human BM-MSCs at the peak (16 dpi) or
chronic stage (27 dpi) of EAE improved functional outcomes and
reduced inflammatory cell infiltration and demyelination (Bai
et al., 2009). In contrast to previous findings from mouse MSC
grafts (Zappia et al., 2005; Gerdoni et al., 2007), human BM-
MSCs migrated to the CNS within 24 h, where they persisted
for up to 45 days (albeit with decreasing numbers). Similarly, the
IV transplantation of human BM-MSCs at 3 dpi or at onset (12
dpi) improved functional outcomes and reduced inflammatory
cell infiltration, including pro-inflammatory Th1 and Th17 cells,
while increasing the number of anti-inflammatory Th2 cells
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and levels of anti-inflammatory cytokines (Guo et al., 2013).
Furthermore, greater quantities of oligodendrocyte lineage cells
were observed surrounding lesions.
Beyond the cells themselves, MSC-derived EVs have
received considerable attention as a prospective MS therapy.
Human AD-MSC EVs, when delivered IV to Theiler’s murine
encephalomyelitis virus-induced demyelinating disease mice
(Laso-García et al., 2018) or EAE mice (Jafarinia et al., 2020),
were found to improve functional outcomes and decrease
inflammatory infiltrates, with evidence of reduced demyelination
in the latter model. Likewise, upon IV administration at
peak mouse EAE, human placental MSC-derived EVs yielded
improved motor function and myelination (Clark et al.,
2019) while EVs from IFN-γ stimulated human BM-MSCs
increased Treg cell numbers with a concomitant decrease in
neuroinflammation and demyelination (Riazifar et al., 2019).
Early/prophylactic IV administration of rat BM-MSC EVs,
when utilized in a spinal cord homogenate-induced rat EAE
model, were found to induce a substantial polarization of CNS
microglia toward an anti-inflammatory M2-like state, with
improved behavioral outcomes and decreased inflammation
and demyelination (Li et al., 2019). Ex vivo functionalization
of EVs is also a promising aspect of this acellular approach,
with, for example, mouse BM-MSC derived EVs adorned with
a myelin-binding aptamer found to suppress inflammation
and demyelination in EAE mice (Hosseini Shamili et al.,
2019). The aptamer-modified EVs yielded improved clinical
scores compared to the non-modified EVs when employed
prophylactically. While EVs of various sources are under
investigation as a distinct therapeutic intervention in several
clinical trials, none are yet being conducted in the context of MS.
Extensive preclinical evidence supporting the paracrine and
immunomodulatory effects of MSCs (or their acellular products)
in preclinical models of MS, as well as safety and feasibility
data from clinical study in other disease contexts, has seen their
adoption as the main nHSC source for clinical trials to date.
Preclinical Evidence for NSCs
As self-renewing, multipotent cells capable of differentiating
into functional neurons and glial cells, NSCs are apposite to
therapeutic applications in the CNS. Small populations of NSCs
are found in the subcortical white matter (Nunes et al., 2003)
and the regions of adult neurogenesis (subventricular zone (SVZ)
and sub-granular zone of the hippocampus), and the discovery
that proliferating NSCs can be maintained in culture (Reynolds
and Weiss, 1992) inspired the study of NSC transplantation as a
therapeutic approach for CNS pathologies, including PMS.
In the context of EAE, the IV and ICV transplantation
of SVZ NSCs before disease onset (10 dpi), at onset (15
dpi), and the peak of disease (22 dpi) have ameliorated
functional deficiencies in mice. Transplanted NSCs localized
to areas of brain with demyelination and axonal loss within
one-month post-transplantation (Pluchino et al., 2003), with
migration to the lesion via chemotaxis reliant on the expression
of very late antigen-4 (VLA-4) adhesion molecules and the
activation of G-coupled protein receptors (Pluchino et al.,
2005). Histopathological analysis demonstrated that a significant
fraction of transplanted NSCs differentiated into OPCs, and
ultimately reduced glial scarring at the lesion sites. Additionally,
the IV transplantation of NSCs during chronic EAE also
improved functional outcomes by promoting apoptosis of pro-
inflammatory T-cells and reducing inflammatory immune cell
infiltrate (Pluchino et al., 2005). To further enhance the anti-
inflammatory effects of NSC transplants in EAE, NSCs from the
SVZ were genetically engineered to secrete the anti-inflammatory
cytokine IL-10 (Yang et al., 2009). When transplanted IV or ICV
before disease onset (10 dpi), at the peak of disease (22 dpi),
or during the chronic phase (30 dpi), grafted IL-10-secreting
NSCs were found to amplify the therapeutic effects observed
with control NSC transplants (Yang et al., 2009). The therapeutic
properties of human NSCs have also been demonstrated in
non-human primate models of EAE, where decreased disease
severity and improved functional outcomes were observed in
both IT- and IV-injected animals, with the IV-treated cohort
demonstrating the greater improvement along with a substantial
survival benefit (Pluchino et al., 2009). Human NSC xenografts
survived undifferentiated for up to 3 months after administration,
distributing to perivascular inflammatory CNS regions and
attenuating T cell proliferation and dendritic cell maturation.
The initial expectation of NSC therapeutics was differentiation
into neural cells and incorporation into the damaged CNS.
However, it has become clear from more recent preclinical
studies that these outcomes are secondary to the effects of
immunomodulation and the promotion of neuroprotection
and homeostasis (Smith et al., 2020), the so-called ‘bystander
effect,’ with NSCs possessed of a therapeutic plasticity allowing
them to respond to endogenous (patho)physiological stimuli
(Martino and Pluchino, 2006). In the context of PMS, the
immunomodulation of MPs by transplanted NSCs is very
promising. Preclinical evidence from mouse models of EAE
suggests that NSCs can alter the proinflammatory phenotypes
of MPs by sequestering the extracellular immunometabolite
succinate and secreting anti-inflammatory PGE2 in response
(Peruzzotti-Jametti et al., 2018). Transplanted NSCs home to
meningeal perivascular areas where they localize in close contact
with MPs, which in turn undergo metabolic reprogramming
toward anti-inflammatory oxidative phosphorylation, with
a resultant amelioration of chronic neuroinflammation
and functional recovery in EAE mice. Notably, similar
results were found using both somatic NSCs and iNSCs
(Peruzzotti-Jametti et al., 2018).
Given these promising findings but otherwise limited
accessibility of NSCs, there is a demand for more practical sources
of NSCs to support clinical study, thus inspiring preclinical
investigations of ESCs, iPSCs, and iNSCs.
Preclinical Evidence for ESC-Derived
Cells
Embryonic stem cells are pluripotent cells derived from the inner
cell mass of the blastocyst and – of interest to MS therapeutic
applications – they can be differentiated into NSCs or OPCs (Piao
et al., 2015; Zhao and Moore, 2018; Chanoumidou et al., 2020).
An IV injection of ESC-NSCs on the day of EAE immunization
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delayed the onset of disease in mice, reduced clinical scores,
and decreased both inflammation and demyelination (Cao
et al., 2011). When administered at 10 dpi, the transplants still
ameliorated EAE symptoms, inhibiting the proliferation and
cytokine production of T cells via the secretion of LIF.
As observed with MSCs, xenografts of human ESC-NSCs
yielded similar results. Human ESC-NSCs transplanted ICV
before disease onset (10 dpi) in mouse models of EAE reduced
axonal damage and demyelination, decreased the quantity of
encephalitogenic T cells, and ultimately improved clinical scores
(Aharonowiz et al., 2008). While transplanted human ESC-NSCs
were found to migrate to the brain parenchyma, differentiation
into mature oligodendrocytes was not observed and the extent
of remyelination was negligible. Similarly, in JHMV mouse
models of MS, intraspinal injection of human ESC-NSCs were
found to survive in the spinal cord parenchyma for only
1 week post-transplantation, but through immunomodulatory
and paracrine effects the cells improved functional outcomes,
reduced demyelination/increased remyelination, and decreased
neuroinflammation with increased CD4+CD25+FOXP3+ Tregs
and depleted CD5+ T cells in the spinal cord (Chen et al.,
2014). In vitro studies found that human ESC-NSCs reduced
T cell proliferation and, as observed in vivo, increased the
number of Tregs.
Although ESC-derived NSCs have shown promising
preclinical results, their use is burdened with ethical concerns
over the source of the cells, as the collection of ESCs destroys
the donor blastocyte. Furthermore, residual pluripotency from
contaminating undifferentiated ESCs remains a safety issue.
Thus, alternative non-ESC sources are favored for future
clinical applications.
Preclinical Evidence for iPSC-Derived
Cells
Preclinical evidence for the feasibility of mouse iPSC-derived cells
for autologous transplantation in MS was first demonstrated in
EAE (Laterza et al., 2013). At the peak of disease, iPSC-derived
NSCs were transplanted ICV into the cisterna magna, resulting
in reduced demyelination and axonal damage, lower quantities
of infiltrating inflammatory cells, improved functional outcomes,
and the activation of the LIF pathway, as described for ESC-
NSCs (Cao et al., 2011). Neither toxicity nor tumorigenicity
was observed (Laterza et al., 2013). Furthermore, iPSC-NSCs
displayed homing effects like those of somatic NSCs (Pluchino
et al., 2003), and were found to localize to either demyelinating
lesions or sites of increased inflammatory cell infiltration. In
line with the bystander hypothesis, most of the transplanted
cells did not differentiate and replace damaged neural cells,
but rather their regenerative effects stemmed from the iPSC-
NSC secretion of LIF, a neuroprotective, trophic cytokine
that promotes endogenous OPC and oligodendrocyte growth
(Laterza et al., 2013). Similarly, a later study performed ICV
transplants of iPSC-NSCs at peak of disease (18 dpi) and observed
amelioration of EAE symptoms and decreased T cell infiltration
(Zhang et al., 2016).
Induced pluripotent stem cells can be differentiated into
specific neural cell types in vitro, including oligodendrocytes
or OPCs. In PMS there is a loss of endogenous OPC
functionality and thus attempts have been made to replace
these cells with pre-differentiated iPSC-OPC transplants. When
transplanted ICV into marmoset and mouse models of
EAE, iPSC-OPCs were shown to decrease inflammatory cell
infiltration, reduce demyelination, and improve functional
outcomes through bystander effects, with minimal transplanted
cells surviving within the CNS parenchyma. However, if
transplanted directly into the parenchyma, histopathological
analysis revealed that the majority of iPSC-OPCs differentiated
into mature oligodendrocytes capable of remyelinating axons, as
observed via electron microscopy, while the remainder retained
their OPC characteristics or differentiated into astrocytes
(Thiruvalluvan et al., 2016).
Nevertheless, iPSC technology faces a number of hurdles
to be addressed before successful clinical translation. There is
growing evidence that the epigenetic signature of the donor
cell can be maintained after iPSC induction. This can lead
to issues of immune rejection of the transplants (Zhao et al.,
2011), or unexpected iPSC functions. In one example, iPSC-
NSCs generated from blood samples of PPMS patients lacked
the neuroprotective phenotype observed in control iPSC-NSCs
when transplanted into cuprizone-induced mouse models of
demyelination (Nicaise et al., 2017). Furthermore, the two-step
induction process required to generate iPSC derived neural
cells and the expansion needed to produce sufficient cell
counts for transplants is very lengthy, increasing the chance of
genetic instability leading to tumorigenicity upon transplantation
(Lee et al., 2013).
Thus, despite potentially exciting in vivo results, iPSCs
and iPSC-derived neural cells still face substantial barriers to
clinical translation.
Preclinical Evidence for iNSCs
In recent years iNSC technology has emerged as a promising
stem cell-based approach to CNS regeneration. iNSCs can be
directly transdifferentiated from somatic cells such as fibroblasts,
bypassing a potentially hazardous pluripotency stage and,
in the case of autologous transplants, largely circumventing
immunogenicity concerns.
Several studies have shown that iNSCs can be stably expanded
in vitro and, like NSCs, secrete pro-regenerative molecules
such as glia cell-derived neurotrophic factor (GDNF) and brain
derived neurotrophic factor (BDNF) (Gao et al., 2017). Moreover,
transplanted iNSCs have demonstrated long-term functional
integration into the CNS in vivo, highlighting their potential for
regenerative applications (Hemmer et al., 2014).
In shiverer mouse models of dysmyelination, iNSCs
transplanted into the cerebellum of post-natal day 1 pups
were able to differentiate, albeit slowly over 10 weeks, into
functional oligodendrocytes capable of myelination (Lujan
et al., 2012). Similarly, iNSCs grafted into the chronically
demyelinated corpus callosum of cuprizone-treated mice
were found to differentiate along oligodendrocyte and
astrocyte lineages, although many remained undifferentiated
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(Sullivan et al., 2020). While iNSC transplantation was not
found to mitigate demyelination in this model, endogenous
oligodendrocytes and proliferating oligodendrocyte progenitors
were increased in iNSC recipients. Notably, astrogliosis was
significantly reduced in mice receiving transplanted iNSCs,
with a concomitant amelioration of motor deficits (Sullivan
et al., 2020). In the more PMS-relevant model of EAE,
iNSCs transplanted ICV were found to be therapeutically
equivalent to their somatic NSC counterparts, migrating to
meningeal perivascular areas of EAE-affected mice where
they reprogrammed pro-inflammatory MPs with resulting
amelioration of chronic neuroinflammation and associated
behavioral deficits (Peruzzotti-Jametti et al., 2018).
Overall, several putative stem cell therapies have demonstrated
compelling preclinical safety and efficacy data in the
context of MS models, with a consensus on the beneficial
bystander/paracrine effects of the transplants, including
during more chronic timepoints. Going forward, further
characterization of the mechanisms of action, in support of
optimized administration variables such as the timing, route, and
dose of cells delivered, will be invaluable in translating preclinical
evidence into clinical study.
CLINICAL STUDIES OF STEM CELL
THERAPIES IN PROGRESSIVE
MULTIPLE SCLEROSIS
Despite a wealth of preclinical data supporting the potential of
cell therapies in treating neuroinflammatory conditions such as
MS, definitive clinical evidence is lacking (Smith et al., 2020).
While the last two decades have seen numerous early phase
clinical trials of putative stem cell therapies in treating MS,
with compelling evidence of the safety and feasibility of the
approach, there is a strong need for more robust efficacy data to
assert the translational potential of the approach. Most published
clinical trial data relates to small safety and tolerability studies
not statistically powered or appropriately controlled to infer
therapeutic benefit, while the heterogeneity of larger studies
has made it difficult to measure the efficaciousness of specific
interventions. Reported trials exhibit variability in a diversity of
parameters, including the makeup of the patient cohort, trial
design, and nature of the therapy (Smith et al., 2020). While
suggestions of beneficial outcomes often emerge from these
clinical studies, larger and/or more rigorous studies are needed
to discern signal from noise before we can gauge the potential
impact of emerging stem cell therapies on the lives of PMS
patients (Pluchino et al., 2020). The following is an overview
of clinical studies in support of the therapeutic use of stem
cell therapies, with a particular focus on nHSC interventions
(summarized in Supplementary Table 1).
Clinical Evidence for HSCs in PMS
Some of the earliest clinical evidence of the utility of cell therapy
in treating MS has arisen serendipitously, with reports of MS
patients experiencing clinical improvements after undergoing
immunoablation and allogeneic bone marrow transplantation
for the treatment of concomitant leukemic or lymphoid
malignancies (van Bekkum et al., 1996; McAllister et al., 1997).
Chemotherapeutic depletion of autoreactive immune cells
followed by reconstitution through HSC transplantation (HSCT,
employing bone marrow, peripheral blood, or umbilical cord
blood sources) has been undergoing clinical study for several
decades (Bakhuraysah et al., 2016; Muraro et al., 2017a; Oliveira
et al., 2021), including in patients with PMS (Fassas et al.,
1997), with beneficial functional outcomes commonly associated
with the treatment. While intervention-associated morbidity and
mortality has decreased substantially since the earliest reports
(Snowden et al., 2017; Das et al., 2019), there remain ongoing
efforts to delineate the optimal compromise between efficacy
and safety with regards to the immunoablative conditioning
regime (Das et al., 2019; Miller et al., 2021). Autologous HSCT is
preferred over allogeneic transplants due to a significantly higher
risk of adverse events such as graft-versus-host disease in the
latter (Lu et al., 2010), as well as a lack of supporting clinical data
for allogeneic grafts (Sharrack et al., 2020).
Evidence from long-term clinical studies points to beneficial
effects of autologous HSCT in impeding disability worsening
over the 5–10 years post-transplant (Muraro et al., 2017b; Boffa
et al., 2021) with an impact exceeding that of DMTs (Muraro
et al., 2017a), however, the efficacy of the treatment appears
to favor younger patients, those with RRMS, and those with
lower disability scores. On the recommendations of groups
such as the (United States) National Multiple Sclerosis Society
(Miller et al., 2021) and European Society for Blood and Marrow
Transplantation (Sharrack et al., 2020), autologous HSCT may be
beneficial for the treatment of active RRMS that is refractive to
current DMTs (or in cases wherein these are contraindicated).
Indeed, some appraisals suggests that HSCT may represent a
cost-effective alternative to DMTs for the treatment of RRMS
(Burt et al., 2020), however, larger studies are ongoing to ascertain
whether HSCT is truly advantageous to current best standards
of care [e.g., (Burt et al., 2019; Zhukovsky et al., 2021), and
the BEAT-MS trial, NCT04047628]. While promising for the
treatment of RRMS, the weight of clinical evidence suggests
that autologous HSCT has limited efficacy in treating chronic
PMS without superimposed disease activity (Bowen et al., 2012;
Miller et al., 2021).
This observation supports the concept of a switch from an
adaptive immune response mediated by infiltrating lymphoid
cells during active/relapsing MS toward a compartmentalized
CNS inflammation with a substantial (non-hematopoietic)
MP-driven innate immunity component during PMS
(Pluchino et al., 2020).
Clinical Evidence for MSCs in PMS
In terms of a putative “regenerative” therapies, non-
hematopoietic cell sources are typically employed. MSCs have
received the most attention, both with regards to applications
in MS (Oliveira et al., 2019) and more generally (Tavakoli
et al., 2020), although their therapeutic activity in the neural
context appears to derive primarily from immunomodulatory
and trophic effects on the pathobiology rather than integration
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and cell replacement (Freedman et al., 2010; Dulamea, 2015;
Wu et al., 2020).
Most of these studies have employed autologous BM-MSCs
or AD-MSCs (occasionally in the form of a stromal vascular
fraction, AD-SVF, a heterogeneous cell fraction including MSCs,
HSCs, and various myeloid and lymphoid cells, amongst others),
but allogeneic MSCs from umbilical cord or placental sources
have also been trialed. A number of phase 1 clinical studies have
demonstrated the feasibility and safety of the IV (Cohen et al.,
2018; Feng et al., 2019; Iacobaeus et al., 2019) or IT (Mohyeddin
Bonab et al., 2007; Sahraian et al., 2019) administration of
BM-MSCs, although in one study a large combined IT and
intracisternal dose of MSCs (100× 106 cells) was associated with
transient encephalopathy, with seizures in one recipient (Yamout
et al., 2010). In several of these pilot studies hints of therapeutic
benefit were observed, but small enrolment sizes and a lack of
controls preclude an assessment of efficacy.
An ongoing phase 1 study (NCT03069170) is comparing
IV and IT BM-MSC administration routes with respect to
primary outcomes of magnetic resonance imaging (MRI) metrics,
safety, and functional changes, while a recent case report
describes reduced radiological inflammatory activity and clinical
stabilization in a RRMS patient receiving multiple IT and IV
treatments over a period of 4 years (Hou et al., 2013). Notably,
the patient received treatments of both autologous BM-MSCs and
allogeneic UC-MSCs with adverse events reported only with the
allogeneic treatment (Hou et al., 2013), but these were minor
and may relate to the larger dosages employed in the IV UC-
MSC transplants.
In other phase 1 clinical study of allogeneic sources serious but
transient adverse events (including an anaphylactoid reaction and
superficial thrombophlebitis) were reported in the highest-dose
(600× 106 cells) IV placental MSC treatment group of a placebo-
controlled study (Lublin et al., 2014), whereas only minor
transient reactions (dizziness, headache, irritation) were reported
in a very small study of multiple UC-MSC treatments (seven IV
administrations per patient, each 1–6× 106 cells/kg body weight)
(Meng et al., 2018). Both studies included participants with SPMS
and generated some early evidence of disease stabilization and
mitigation of clinical symptoms.
In phase 1 safety studies of autologous AD-SVFs, three
IT administrations of up to 14.2 × 106 cells did not lead
to serious adverse events (Siennicka et al., 2016), whereas a
study of participants receiving between 1 and 15 ICV cell
administrations revealed several instances of treatment-related
transient meningismus and additional complications related to
the use of implanted conduits in delivering the cells (Duma et al.,
2019). The safety of autologous endometrial MSCs administered
IV to women with SPMS is also currently being explored in a
placebo-controlled phase 1 study in Iran (Iranian Registry of
Clinical Trials: IRCT20190711044175N1).
Studies of the efficacy of MSCs on MS have likewise involved
both autologous and allogeneic sources, with a mix of IV and
IT administration. Uncontrolled phase 1/2 studies have further
affirmed the safety of the intervention, but with clinical outcomes
ranging from no significant effect (Dahbour et al., 2017) through
to short-to-intermediate-term stabilization of disease activity
and/or progression (Stepien et al., 2016), modest improvements
in function or quality of life (Riordan et al., 2018), and long-term
reductions in relapse occurrence (Lu et al., 2020).
In a small, placebo-controlled phase 2 crossover clinical
study of IV-delivered autologous BM-MSCs, evidence of non-
significant decreases in MRI lesion activity and circulating Th1
cell counts is reported (Llufriu et al., 2014).
A further phase 2 study of multiple IV administrations of UC-
MSCs found treatment-associated reductions in clinical scores
and symptoms, and number of relapses, with serum analyses
suggesting a shift from Th1-like (pro-inflammatory) to Th2-
like (anti-inflammatory) immune responses in treated patients
(Li et al., 2014).
The ambitious MEsenchymal StEm cells for Multiple Sclerosis
(MESEMS) study, a placebo-controlled, crossover phase 1/2
study of autologous BM-MSCs, incorporated multiple partially
independent studies from different centers under harmonized
protocols to overcome funding constraints and improve
statistical power (Uccelli et al., 2019). Preliminary results support
the safety of the approach (single IV injection of 1–2 × 106
MSCs per kg of body weight), but with no impact on the number
of contrast-enhancing lesions by MRI at 24 weeks, the primary
efficacy endpoint (Uccelli et al., 2020).
Any benefit of MSC transplantation in treating PMS
specifically is often obfuscated by trial cohorts including both
RRMS and PMS patients. Even those trials focused specifically
on PMS often enroll participants with active PMS, a population
apparently more responsive to the immunomodulatory
effects of MSCs.
In a placebo-controlled phase 2 crossover study comparing the
IT and IV administration of autologous BM-MSCs to participants
with PPMS and SPMS, those having had a relapse or MRI activity
in the year prior to treatment were more responsive to treatment
(Petrou et al., 2020). Overall, the inhibition of disease progression
and beneficial functional outcomes were observed, with IT
administration eliciting a more significant effect than IV, and two
MSC injections (at a 6-month interval) proving more efficacious
than a single dose. This study was a follow-up to an earlier
single-arm phase 1/2 trial of IT administration of autologous BM-
MSCs to MS and amyotrophic lateral sclerosis patients in which
acute immunomodulatory effects and a statistically significant
improvement in EDSS scores were observed in the MS cohort
during 6 months of follow-up (Karussis et al., 2010).
Other PMS-specific trials include a phase 2 study of IT
autologous BM-MSC administration in which no significant
improvements where observed in PMS patients (Bonab et al.,
2012), and a placebo-controlled, dose-ranging phase 1/2 study of
IV autologous AD-MSCs in which inconclusive signs of efficacy
in SPMS were inferred from changes in the number of MRI
lesions and evoked potential parameters (Fernandez et al., 2018).
On the other hand, a phase 1/2 study of combined IT
and IV UC-MSCs in SPMS patients showed decreased relapse
frequency and/or lesion severity, improvement in clinical
scores, and evidence of peripheral immunomodulation (Lu
et al., 2013). Similarly, a single-arm phase 1/2a study of IV
autologous BM-MSCs in SPMS patients revealed improvements
in visual acuity, reduction of visual evoked response latencies,
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and protection of the optic nerve area by optical coherence
tomography (OCT) in the 6 months following transplantation
(Connick et al., 2011, 2012).
Several additional randomized phase 1/2 trials have been
completed but the results not yet reported, including placebo-
controlled studies of IV-administered autologous BM-MSCs in
RRMS patients and a crossover study in RRMS and SPMS
participants, and a study comparing the beneficial effects of
combined IT and IV administration of UC-MSCs (and a follow-
up booster of MSC-conditioned media) with supervised physical
therapy (Alghwiri et al., 2020).
Ongoing clinical studies include a unique phase 1 study
(NCT02795052) comparing IV administration of autologous
BM-MSCs with a combination of IV and intranasal delivery,
currently recruiting participants across various neurological
conditions, including MS (Weiss and Levy, 2016), as well
as a larger, controlled phase 2/3 study of autologous BM-
MSCs on RRMS relapse rates and clinical/radiological outcomes
employing an initial IV dose followed up with an IT booster
(IRCT20191004044975N1).
Progressive MS-specific trials currently underway include a
phase 1/2 placebo-controlled crossover study of IT autologous
BM-MSCs exploring neurophysiological, functional, and
quality-of-life outcomes in both PPMS and SPMS patients
(NCT04749667), a single-arm phase 1/2 studies of the
effects autologous AD-MSCs clinical, radiological, and
immunological measures in SPMS patients (NCT03696485
and IRCT20091127002778N1), and a single-arm phase 2 study of
BrainStorm Cell Therapeutics’ NurOwn product (neurotrophic
factor-expressing autologous BM-MSCs) upon multiple IT
administration to PMS patients (NCT03799718).
In order to increase the regenerative potential of MSCs,
a number of clinical studies by the Tisch MS Research
Center of New York have employed MSC neural progenitors
(MSC-NPs), a subpopulation of mesenchymal cells that exhibit
neuroectodermal lineage characteristics and are likely to be more
CNS compatible while retaining the immunomodulatory and
trophic capabilities of common MSCs (Harris et al., 2012). The
tolerability of the treatment was established by a phase 1 dose-
escalating IT administration study in people with PMS, which
supported feasibility and long-term safety with post-treatment
improvement of clinical scores in 4 (out of 6) participants
(Harris et al., 2016). A follow-up single-arm phase 1 study,
comprising 3 IT treatments of MSC-NPs administered at 3-
month intervals, found an improved mean EDSS score over
12 months of follow-up sustained by 7 (out of 20) participants
at 2 years (Harris et al., 2018, 2021). Effects were found to be
more pronounced in ambulatory (low/medium-disability) SPMS
participants, rather than (non-ambulatory), PPMS participants.
Clinical outcomes also included signs of improved muscle
strength (70% of participants) and bladder function (50% of
participants) (Harris et al., 2018), while cerebrospinal fluid
biomarker changes, including a decrease in CCL2 and increases
in IL-8, HGF, and CXCL12, were found to reflect treatment-
related immunoregulatory and trophic effects (Harris et al.,
2021). These outcomes have inspired an ongoing placebo-
controlled phase 2 crossover trial (NCT03355365), which is
recruiting 50 PMS participants to receive a total of 6 IT
treatments at 2-month intervals, with functional outcomes
(including clinical scores and bladder function) assessed over
36 months of follow-up. Participants in this trial are to be
ambulatory (i.e., EDSS ≤ 6.5) and will be stratified according
to baseline EDSS score and disease subtype (PPMS or SPMS);
an expanded-access study for those that do not meet eligibility
criteria is also planned (NCT03822858).
Clinical Evidence for NSCs and
Pluripotent Stem Cells in PMS
Two dose-response phase 1 safety and tolerability clinical studies
of bona fide allogeneic fetal-derived NSC transplantation in PMS
patients have been conducted.
Clinical trial NCT03269071 (IRCCS Ospedale San Raffaele)
has enrolled 4 cohorts of 3 PMS participants each to receive an
IT dose of 0.7–5.7 × 106 cells/kg, with quality-of-life outcomes
to be assessed, while trial NCT03282760 (Casa Sollievo della
Sofferenza IRCCS) has treated 24 SPMS participants with an ICV
dose of 5–24 × 106 cells each, examining functional, cognitive,
and neurophysiological changes post-treatment. Both trials have
been completed but outcomes are yet to be reported at the
time of writing.
While iPSC-derived cells have begun to see study in other
clinical contexts [e.g., iPSC-derived NSCs in spinal cord injury
(Nagoshi et al., 2020) and iPSC-derived retinal pigment epithelial
cells for treating age-related macular degeneration (Mandai et al.,
2017)], the technology has yet to undergo trials in MS despite
its potential (Fossati and Douvaras, 2014). Concerns regarding
the safety of pluripotent cells sources is likely to be a key factor
impeding their clinical development (Ortuño-Costela et al.,
2019), although case reports of embryonic stem cell transplants
in MS patients have been published (Shroff, 2016). The use of
iNSCs, generated by direct reprogramming of somatic cells and
thus bypassing the pluripotent state, may represent an attractive
alternative approach (Xie et al., 2016).
Thus, evidence to date supports the safety and feasibility
of HSC and MSC therapies in MS, with immunomodulatory
and/or trophic mechanisms of action providing modest, transient
clinical benefits in RRMS or active PMS. More robust clinical
studies and systematic reviews (see e.g., Rahim et al., 2019) will be
required to establish the extent of these benefits and whether cell
therapies provide advantages over current best standards of care.
There is little current clinical evidence supporting the efficacy
of HSC or MSC transplants in treating PMS, which will likely
require novel mechanisms through which to not only halt disease
progression but also foster CNS repair. NSCs, somatic or induced,
may be key to providing the regenerative potential necessary to
combat the gradual accumulation of disability arising from PMS,
but clinical studies in this area are in their infancy.
CONCLUSION
While the treatment of MS continues to advance, therapeutic
options remain restricted to ameliorating or preventing relapses
and acute inflammation events in RRMS or active PMS. There are
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no proven interventions able to halt the gradual accumulation
of disability associated with PMS, let alone effectively promote
repair of the damaged CNS. The prospect of stem cell therapy
brings with it great promises of regenerative potential, yet
the weight of preclinical and clinical evidence to date points
to immunomodulatory and trophic effects that are most
advantageous to addressing relapsing/active forms of the disease.
The best hopes for an impact on PMS perhaps lay with NSCs,
either somatic or transdifferentiated, which have given rise to
compelling preclinical evidence for the amelioration of chronic
neuroinflammation through novel mechanisms of action, but
have yet to see substantial clinical study in the context of
MS. Ultimately, while the safety and feasibility of stem cell
transplantation has been demonstrated across various cell types
and administration routes, there remains a need for larger and/or
more rigorous studies to quantify the benefits of stem cell therapy
and demonstrate an advantage over current best standards of
care. Whether stem cell therapies have the potential to repair the
PMS CNS in a clinical setting remains to be seen.
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